Skip to content

Folic Acid and Creatine as Therapeutic Approaches for Lowering Blood Arsenic

Folic Acid and Creatine as Therapeutic Approaches for Lowering Blood Arsenic

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01050556
Acronym
FACTA
Enrollment
600
Registered
2010-01-15
Start date
2010-09-30
Completion date
2011-06-30
Last updated
2012-08-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

High Blood Arsenic Due to Chronic Arsenic Exposure

Keywords

arsenic, folate, folic acid, creatine, arsenicosis, nutrition

Brief summary

The purpose of this study is to determine whether folic acid, alone or together with creatine supplementation, can lower blood arsenic concentrations and improve the ability to detoxify arsenic.

Detailed description

Approximately 140 million people in over 70 countries are chronically exposed to arsenic (As)-contaminated drinking water at concentrations far exceeding the World Health Organization standard of 10 µg/L. As is a carcinogen known to cause cancers of the skin, bladder, and lung, as well as ischemic heart disease and neurologic impairments. Methylation of ingested inorganic arsenic (InAs) to methylarsonic-(MMA) and dimethylarsinic acids (DMA) relies on folate-dependent one carbon metabolism, utilizing S-adenosylmethionine (SAM) as the methyl donor, and facilitates urinary As elimination. The results from our Nutritional Influences on Arsenic Toxicity (NIAT) study indicate that folate deficiency and hyperhomocysteinemia (HHcys) are associated with a reduced capacity to methylate arsenic and are risk factors for arsenic-induced skin lesions. Furthermore, folic acid (FA) supplementation does indeed facilitate As elimination and significantly lowers blood As concentrations in individuals who are folate deficient. We have also determined that blood As is a good biomarker of As exposure and is directly associated with the risk for As-induced skin lesions. Collectively, the implication of these findings is that FA has enormous therapeutic potential for ameliorating the long-term health consequences of arsenic exposure for the many populations at risk. However, several fundamental questions remain and will be addressed in this study. This trial is designed to determine 1) whether FA supplementation lowers blood As concentrations in the general Bangladeshi population, 2) at what time point a nadir in blood As is achieved, and 3) whether creatine supplementation, alone or in addition to 400 µg/d FA, will spare methyl groups, resulting in lower blood As, lower homocysteine (Hcys) concentrations, and increased methylation of As. The creatine arms are based on multiple studies that show that urinary creatinine concentrations are a very strong predictor of As methylation. The final step in creatine biosynthesis is the methylation of guanidinoacetate to creatine; this process consumes 50-75% of all SAM-derived methyl groups and is also responsible for 50-75% of all Hcys biosynthesis. Thus, this trial will test the hypothesis that creatine supplementation, which shuts down endogenous creatine biosynthesis, will spare methyl groups, lower Hcys, and increase As methylation.

Interventions

OTHERPlacebo

daily, 24 weeks

DIETARY_SUPPLEMENTfolic acid

400 ug/d for 12 or 24 weeks

DIETARY_SUPPLEMENTcreatine

3 mg/d for 12 weeks

DIETARY_SUPPLEMENTcreatine + folic acid

3 mg creatine/d + 400 µg folic acid/d for 12 weeks

Sponsors

National Cancer Institute (NCI)
CollaboratorNIH
Columbia University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
20 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* Currently exposed to arsenic via contaminated drinking water * Well water arsenic concentration \> 10 ug/L * Between the ages of 20 and 65

Exclusion criteria

* Women who are currently pregnant or plan to become pregnant within the next 6 months * Currently taking nutritional supplements * Known renal disease * Participation in any other clinical trial

Design outcomes

Primary

MeasureTime frame
blood arsenic concentrations24 weeks

Countries

Bangladesh

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 15, 2026